Rumi Therapeutics Licenses PDE2 Inhibitor for Fragile X

The company has secured rights to the investigational drug candidate RTX-7340 to target Fragile X syndrome.

Updated on Oct. 27, 2026 in Biotech

Isometric editorial illustration of a neural cluster in a glass dish on a laboratory bench, representing pharmaceutical research. — Rumi Therapeutics has signed a licensing agreement with Enthorin Therapeutics to advance the development of RTX-7340 for the treatment of Fragile X syndrome. AI Illustration. Upload story photo >

Rumi Therapeutics signed a licensing agreement with Enthorin Therapeutics for the IND-ready drug candidate RTX-7340. The agreement aims to advance research for treating Fragile X syndrome.

Why it matters

This partnership enables Rumi Therapeutics to expand its focus from discovery-stage research toward clinical development for neurodevelopmental disorders.

RTX-7340 is an investigational PDE2 inhibitor that has demonstrated the correction of disease-associated EEG abnormalities in Fmr1-knockout mice. Its safety and efficacy in humans have not yet been established.

The players

Rumi Therapeutics

A biotechnology firm based in New York that focuses on advancing research from discovery-stage projects to clinical development.

Enthorin Therapeutics

A biopharmaceutical entity that holds the initial rights to the PDE2 inhibitor drug candidate RTX-7340.

The details

Rumi Therapeutics plans to utilize preclinical findings from human organoid studies to guide the selection of neurophysiological measures. The firm also intends to investigate whether PDE2 inhibition can be applied to other neurodevelopmental conditions.

October 27, 2026: Rumi Therapeutics announced the licensing agreement.

The Tech Race

This drug candidate advances the industry shift toward targeting specific neurophysiological pathways like PDE2 inhibition to improve synaptic plasticity. This marks a departure from symptom-based treatments toward therapies designed to address the underlying cellular mechanisms of neurodevelopmental disorders.

As RTX-7340 remains in the investigational stage, there are currently no immediate changes to treatment options or drug availability for patients. Future clinical trials will determine if this research can eventually provide a viable therapeutic pathway for those affected by Fragile X syndrome.

The takeaway

This licensing deal highlights the growing reliance on translational research models that bridge animal studies with human organoid analysis. Advancements in synaptic plasticity research continue to provide new avenues for addressing complex neurodevelopmental challenges.